Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Precision in Vaccine Target Prediction: These advancements in EvaxMHC's performance are anticipated to further enhance Evaxion's ability to accurately predict vaccine targets Christian Kanstrup, Evaxion's CEO, comments: "Our results demonstrate significant improvements in the prediction of peptide-MHC interactions, particularly for MHC class II molecules, which have historically been difficult to predict accurately. With this advancement on AI-Immunology™ we now have a more reliable and effective tool for d ...